What we do
Our ResearchOur primary project is a next generation topical treatment of eczema (atopic dermatitis) for mild to moderate symptoms
Our primary project is a next generation topical treatment of eczema (atopic dermatitis) for mild to moderate symptoms
Administered topically via a water based cream. Can easily be administered by the patients themselves
Dampened T-helper responses and onset of cells to target area both reduces sensations of itch and supports the regeneration of the damaged tissue, thus reversing the vicious cycle of itching and worsening AD symptoms.
Does not completely depress the immune system, but insteads acts through temporarily inhibiting mast cell degranulation, dendritic cell activation, in addition to stimulating IL-10 production. Hence, the immune system is directed towards immune regulation and not blunt immunesupression. This allows for continued symptom inhibition beyond the treatment period.
Founded by Prof. Anna-Lena Spetz, our journey began with the serendipitous discovery of the single-stranded oligonucleotide that we call TIR-01, a remarkable compound with profound immunomodulatory properties. Today, TIRmed stands at the forefront of new innovations within topical treatments, shaping the future treatments for inflammatory skin diseases.
Founder, Chief Scientific Officer
"There is a large unmet need for effective, non-steroid topical treatments for patients suffering from mild-moderate eczema, especially for children and young adults. TIRmed´s immunoregulatory cream has the potential to fill this gap"
With years of experience in the senior care industry, our compassionate team of caregivers and professionals is committed to delivering personalized care tailored to the specific requirements.
Former consultant at BCG. Strategy specialist, with experiences as advisor for multiple pharma deals and large strategic projects. Previously engaged in raising capital in SME settings. Masters from London Business School.
30 years in immunology research with previous roles at Karolinska Institutet, Institut Pasteur, and Dana-Farber Cancer Institute, Harvard Medical School.
30 years of experience in the pharmaceutical industry, including clinical trials and regulatory work.Leadership roles at Astra and Kabi aswell as CEO of a CRO and several pharmaceutical and life science SMEs(listed and private).
Over 30 years of experience at Astra Zeneca in senior leadership roles, including Director of Chemistry and Project Leader in the CNS and Pain Control therapeutic areas. Expertise in drug discovery, intellectual property strategy, and clinical development.
